Lercanidipine. (R)- | CAS#185197-70-0 | L-type calcium channel blocker

MedKoo Cat#: 598610 | Name: Lercanidipine. (R)-

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lercanidipine. (R)- is enantiomer of antihypertensive drugs Lercanidipine, that acts by blocking L-type calcium channels, allowing relaxation and opening of blood vessels.

Chemical Structure

Lercanidipine. (R)-

CAS#185197-70-0

Theoretical Analysis

MedKoo Cat#: 598610

Name: Lercanidipine. (R)-

CAS#: 185197-70-0

Chemical Formula: C36H41N3O6

Exact Mass: 611.2995

Molecular Weight: 611.73

Elemental Analysis: C, 70.68; H, 6.76; N, 6.87; O, 15.69

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Lercanidipine. (R)-; (-)-Lercanidipine; (R)-Lercanidipine;

IUPAC/Chemical Name

3-(1-((3,3-diphenylpropyl)(methyl)amino)-2-methylpropan-2-yl) 5-methyl (R)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

InChi Key

ZDXUKAKRHYTAKV-MGBGTMOVSA-N

InChi Code

InChI=1S/C36H41N3O6/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27/h7-19,22,30,33,37H,20-21,23H2,1-6H3/t33-/m1/s1

SMILES Code

O=C(C1=C(C)NC(C)=C(C(OC)=O)[C@H]1C2=CC=CC([N+]([O-])=O)=C2)OC(C)(C)CN(CCC(C3=CC=CC=C3)C4=CC=CC=C4)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 611.73 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Egan CG, Pontremoli R. Role of the fixed-dose combination lercanidipine-enalapril in renal protection. J Nephrol. 2011 Jul-Aug;24(4):428-37. doi: 10.5301/JN.2011.6271. Review. PubMed PMID: 21279953. 2: Kaila HO, Ambasana MA, Thakkar RS, Saravaia HT, Shah AK. A Stability-indicating High Performance Liquid Chromatographic Assay for the Simultaneous Determination of Atenolol and Lercanidipine Hydrochloride in Tablets. Indian J Pharm Sci. 2011 Jul;73(4):376-80. doi: 10.4103/0250-474X.95612. PubMed PMID: 22707819; PubMed Central PMCID: PMC3374551. 3: Soma MR, Natali M, Donetti E, Baetta R, Farina P, Leonardi A, Comparato C, Barberi L, Catapano AL. Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits. Br J Pharmacol. 1998 Dec;125(7):1471-6. PubMed PMID: 9884075; PubMed Central PMCID: PMC1565732. 4: Lourenço LP, Aguiar FA, de Oliveira AR, de Gaitani CM. Quantitative determination of lercanidipine enantiomers in commercial formulations by capillary electrophoresis. J Anal Methods Chem. 2015;2015:294270. doi: 10.1155/2015/294270. Epub 2015 Mar 2. PubMed PMID: 25821632; PubMed Central PMCID: PMC4363879. 5: Wirtz S, Herzig S. Molecular mechanisms of vasoselectivity of the 1,4-dihydropyridine lercanidipine. Br J Pharmacol. 2004 May;142(2):275-84. PubMed PMID: 15155536; PubMed Central PMCID: PMC1574954. 6: Corsini A, Bonfatti M, Quarato P, Accomazzo MR, Raiteri M, Sartani A, Testa R, Nicosia S, Paoletti R, Fumagalli R. Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes. J Cardiovasc Pharmacol. 1996 Nov;28(5):687-94. PubMed PMID: 8945683. 7: Jabor VA, Coelho EB, Lanchote VL. Enantioselective pharmacokinetics of lercanidipine in healthy volunteers. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Dec 25;813(1-2):343-6. PubMed PMID: 15556551. 8: Fogari R, Mugellini A, Zoppi A, Corradi L, Rinaldi A, Derosa G, Preti P. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens. 2003 Jul;16(7):596-9. PubMed PMID: 12850395. 9: Kaila HO, Ambasana MA, Thakkar RS, Saravaia HT, Shah AK. A Stability-indicating HPLC Method for Assay of Lercanidipine Hydrochloride in Tablets and for Determining Content Uniformity. Indian J Pharm Sci. 2010 May;72(3):381-4. doi: 10.4103/0250-474X.70490. PubMed PMID: 21188053; PubMed Central PMCID: PMC3003177. 10: Angelico P, Guarneri L, Leonardi A, Testa R. Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J Pharm Pharmacol. 1999 Jun;51(6):709-14. PubMed PMID: 10454048. 11: Guarneri L, Angelico P, Ibba M, Poggesi E, Taddei C, Leonardi A, Testa R. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine. Arzneimittelforschung. 1996 Jan;46(1):15-24. PubMed PMID: 8821512. 12: Acanfora D, Trojano L, Gheorghiade M, Picone C, Papa A, Furgi G, Giuliano F, Maestri R, Rengo F. A randomized, double-blind comparison of 10 and 20 mg lercanidipine in patients with stable effort angina: effects on myocardial ischemia and heart rate variability. Am J Ther. 2002 Sep-Oct;9(5):444-53. PubMed PMID: 12237738. 13: Salem II, Idrees J, Al Tamimi JI, Farina P. Selective and rapid liquid chromatography-mass spectrometry method for the determination of lercanidipine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Apr 25;803(2):201-7. PubMed PMID: 15063326. 14: Pedrinelli R, Dell'Omo G, Nuti M, Menegato A, Balbarini A, Mariani M. Heterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients. J Hypertens. 2003 Oct;21(10):1969-73. PubMed PMID: 14508205. 15: Corsini A, Accomazzo MR, Canavesi M, Sartani A, Testa R, Catapano AL, Fumagalli R, Paoletti R, Bernini F. The new calcium antagonist lercanidipine and its enantiomers affect major processes of atherogenesis in vitro: is calcium entry involved? Blood Press Suppl. 1998;2:18-22. PubMed PMID: 9850438. 16: Campo C, Saavedra J, Segura J, Roldán C, Ruilope LM, Parati G. Correlations of smoothness index and trough-to-peak ratio with left ventricular mass index changes induced by lercanidipine in hypertensive patients. A pilot trial. Minerva Med. 2005 Oct;96(5):365-71. PubMed PMID: 16227951. 17: Boralli VB, Coelho EB, Sampaio SA, Marques MP, Lanchote VL. Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers. J Clin Pharmacol. 2009 Feb;49(2):205-11. doi: 10.1177/0091270008327536. Epub 2008 Nov 25. PubMed PMID: 19033449. 18: Angeloni E, Vitaterna A, Lombardo P, Pirelli M, Refice S. Single-pill combination therapy in the initial treatment of marked hypertension: a propensity-matched analysis. Clin Exp Hypertens. 2015;37(5):404-10. doi: 10.3109/10641963.2014.987395. Epub 2014 Dec 12. PubMed PMID: 25496379. 19: Sironi G, Montagna E, Greto L, Leonardi A, Testa R. Haemodynamic effects of lercanidipine in anaesthetized open-chest dogs. Arzneimittelforschung. 1996 Mar;46(3):256-61. PubMed PMID: 8901145. 20: Cerbai E, Mugelli A. Lercanidipine and T-type calcium current. Eur Rev Med Pharmacol Sci. 2018 Jun;22(12):4025-4031. doi: 10.26355/eurrev_201806_15289. PubMed PMID: 29949180.